Welcome!

News Feed Item

Inhalation & Nasal Spray Generic Drugs 2012

NEW YORK, Dec. 12, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:


Inhalation & Nasal Spray Generic Drugs 2012
http://www.reportlinker.com/p01054642/Inhalation--Nasal-Spray-Generic-Drugs-2012 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug



It is no surprise then, that such high revenue originator drugs are attracting interest from prospective generic competitors. Unlike the oral generics market, however, where numerous companies typically compete for a revenue share, relatively few companies have the technology and expertise to compete in the market for generic inhalation and nasal spray products. But for those that are successful, there are significant revenue opportunities.



Overcoming the delivery challenge
While it is possible for companies to develop bioequivalent generic versions of nasal spray products, significant barriers remain to gaining entry into the more lucrative asthma/COPD market. The few generic inhalable products currently approved by the FDA in this therapy area are solutions, generally for delivery via a nebuliser. This is
partly due to developments in the delivery devices, following the phasing out of CFCs in metered dose inhalers (MDIs) in favour of devices that use the more ozone friendly
hydrofluoroalkane (HFA).



Developing a hand-held generic inhaler is no easy task. The bioavailability of the drug in the airway relies on a combination of the drug and the delivery device. To date, companies have been unable to gain marketing approval for bioequivalent generics in the US via the ANDA route. Some generics have been approved in the EU, but these are generally branded products that use proprietary inhalation devices and are, therefore, not pure generics and unlikely to be interchangeable at the pharmacy.



Key questions answered:

What delivery solutions have been found?
Which are the products to watch?
Who's making the running in this sector?




The answer to these and thousands of other key business questions can be found in this new market research study from Espicom. Essential reading for pharma executives, those in the generic field and the commercial community, this 128-page fact-filled report provides a complete and comprehensive review of the issues, trends, products and companies that are shaping the global market in this sector.



Development of generic alternatives in this sector will require some inspired thinking. Maybe not a generic approach at all?



Patent issues
The generic market is undergoing radical restructuring, with much rationalisation of the corporate landscape. In such a competitive environment, companies are now seeking not just new opportunities, but opportunities which combine good profit levels and a degree of product novelty ? both of which are available in the inhalation and nasal spray market.


Side stepping the bioequivalence problem
A few companies have avoided this problem by gaining approval for branded products that use proprietary inhalation devices. Among these are Teva, which has two successful branded asthma inhalers, Proair (salbutamol) and Qvar (beclomethasone dipropionate); and Orion, with its Easyhaler DPI. In October 2011, Teva became the first company to launch a generic salmeterol xinafoate 25mcg pMDI in the UK, following approval by the MHRA in April 2011. The UK marketing authorisation holder for the product, which is branded Neovent/Sereflo, is Neolab Ltd, a UK-based pharmaceutical development company. GSK has been quick to point out that Neovent is a branded product that is not identical to Serevent and, therefore, not an interchangeable generic. This is clearly Teva's approach: its beclomethasone dipropionate HFA nasal aerosol for the treatment of SAR will not be a generic and an NDA was submitted in May 2011 to the FDA.



Gearing up for Seretide/Advair?
Undoubtedly the biggest prize for generic manufacturers will be the current market leader: GSK's Seretide/Advair, which achieved revenue of US$8,247 million in 2011 –
nearly twice the value of its nearest competitor. GSK has US patents for Advair with expiry dates up to July 2025, although the combination patent expired in 2010. In Europe the UK patent has been revoked, but Seretide is protected by Supplementary Protection Certification in other countries until 2013.



At least two generic versions of Seretide/Advair are currently in development. Sandoz and Vectura are jointly developing VR315, a combination product that is widely thought to be generic Seretide/Advair. Sandoz currently has development and commercialisation rights in Europe and other markets, excluding the US. Vectura licensed the US rights to this product to an undisclosed pharmaceutical company in August 2011. Mylan is developing a generic fluticasone+salmeterol combination product, utilising Pfizer's dry powder inhaler delivery platform, following an agreement between the companies in 2011. Mylan is targeting a launch of its generic in Europe in 2015, followed by the US in 2016.

To order this report:
Generic_Drug Industry:
Inhalation & Nasal Spray Generic Drugs 2012

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
First generation hyperconverged solutions have taken the data center by storm, rapidly proliferating in pockets everywhere to provide further consolidation of floor space and workloads. These first generation solutions are not without challenges, however. In his session at 21st Cloud Expo, Wes Talbert, a Principal Architect and results-driven enterprise sales leader at NetApp, will discuss how the HCI solution of tomorrow will integrate with the public cloud to deliver a quality hybrid cloud e...
Is advanced scheduling in Kubernetes achievable? Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, will answer these questions and demonstrate techniques for implementing advanced scheduling. For example, using spot instances ...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...